MHB-042-C

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameMHB-042-C

Drug Alias NameMHB042CMHB-042-C

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SuperTopoi payload

Mechanisms of ActionAnti-Hepatocyte growth factor receptorDNA topoisomerase I inhibitors

TargetsHepatocyte growth factor receptorDNA topoisomerase I

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesMinghui Pharmaceutical (Hangzhou) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMinghui Pharmaceutical (Hangzhou) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A